Medtronic Reports Positive Results with CoreValve and Acquisition of Peak Surgical, Salient Surgical Technologies

Investigators reported that cardiac survival of patients, who were implanted with the 21F CoreValve system in 2005 and 2006, was 77.9 percent at two years and 68 percent at four years; in other Medtronic news, company announces completing the acquisition of Peak Surgical Inc. and Salient Surgical Technologies Inc.

Balloon pump use prior to PCI does not reduce infarct size in STEMI patients without shock

Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction (CRISP AMI) trial.

CERMA Creates Spin-Off Company CERMAVEIN to Commercialise Steam Vein Sclerosis (SVS(TM)) Technology in Varicose Vein Market

French emerging medical technology company CERMA, specialized in the development of innovative and minimally invasive devices in phlebology and oncology, announced today the creation of spin-off CERMAVEIN

IOM to FDA: Ditch the 510(k) clearance program for medical devices

The Institute of Medicine’s much-anticipated independent review of the FDA’s 510(k) clearance program for medical devices recommends that the entire program be scrapped in favor of a new protocol to ensure the devices are safe and effective. Medtronic officials and Sen. Scott Brown (R-Mass.) react.

Most read

Latest

^